Edition:
United Kingdom

Tonix Pharmaceuticals Holding Corp (TNXP.OQ)

TNXP.OQ on NASDAQ Stock Exchange Global Market

3.81USD
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
$3.81
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
15,980
52-wk High
$9.38
52-wk Low
$2.85

Chart for

About

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates,... (more)

Overall

Beta: 2.98
Market Cap(Mil.): $36.27
Shares Outstanding(Mil.): 7.51
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.70 16.58
EPS (TTM): -- -- --
ROI: -- 3.19 10.60
ROE: -- 4.52 14.19

BRIEF-Tonix Pharmaceuticals Appoints Jessica Morris As CEO

* TONIX PHARMACEUTICALS APPOINTS JESSICA MORRIS AS CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

09 Jan 2018

BRIEF-Tonix Pharmaceuticals Completes Positive Pre-Ind Meeting With FDA For TNX-102 SL

* TONIX PHARMACEUTICALS COMPLETES POSITIVE PRE-IND MEETING WITH FDA FOR TNX-102 SL (CYCLOBENZAPRINE HCI SUBLINGUAL TABLETS) AS A CLINICAL CANDIDATE FOR AGITATION IN ALZHEIMER’S DISEASE

12 Dec 2017

BRIEF-Tonix Pharmaceuticals Q3 loss per share $0.77

* Tonix Pharmaceuticals reports third quarter 2017 financial results and provides programs update

07 Nov 2017

BRIEF-Tonix Pharma reports outcomes from CMC guidance meeting with FDA on Tonmya

* Tonix Pharmaceuticals reports outcomes from U.S. FDA breakthrough therapy CMC guidance meeting of Tonmya® (cyclobenzaprine hci sublingual tablets) for PTSD

17 Oct 2017

BRIEF-Tonix Pharmaceuticals enters into purchase agreement, registration rights agreement with Lincoln Park Capital Fund

* On Sept. 28 co entered into purchase agreement, registration rights agreement with Lincoln Park Capital Fund LLC

29 Sep 2017

BRIEF-Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya

* Tonix Pharmaceuticals receives European patent for the active ingredient in Tonmya® (cyclobenzaprine hcl sublingual tablets) Source text for Eikon: Further company coverage:

14 Sep 2017

BRIEF-Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors

* Tonix Pharmaceuticals elects Margaret Smith Bell to the Board of Directors Source text for Eikon: Further company coverage:

14 Sep 2017

BRIEF-Tonix Pharmaceuticals presents additional phase 2 clinical results, ongoing phase 3 trial design of Tonmya at 2017 Military Health System Research Symposium

* Tonix Pharmaceuticals presented additional phase 2 clinical results in military-related PTSD and design of ongoing phase 3 trial at the 2017 Military Health System Research Symposium

29 Aug 2017

BRIEF-Tonix Pharmaceuticals to present at Military Health System Research Symposium

* Tonix Pharmaceuticals to present additional phase 2 clinical results and design of ongoing phase 3 trial in military-related ptsd at the 2017 military health system research symposium Source text for Eikon: Further company coverage:

21 Aug 2017

BRIEF-Tonix Pharmaceuticals Holding reports Q2 loss per share $0.65

* Tonix Pharmaceuticals reports second quarter 2017 financial results and provides programs update

14 Aug 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $147.00 -0.36
Pfizer Inc. (PFE.N) $36.91 -0.03
Novartis AG (NOVN.S) CHF83.04 -0.34
AstraZeneca plc (AZN.L) 5,054.00 +11.00
GlaxoSmithKline plc (GSK.L) 1,359.20 +1.20

Earnings vs. Estimates